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COENEN, A. M. L., N. ATES, T. SRARSFELDT AND E. L. J. M. VAN LUIJTELAAR. Effects of sertittdole on 
sleep-wake states, electroencephalogram. behavioral potterns, and epileptic activity of rats. P HARMACOL BIOCHEM 
BEHAV 51(2/3) 353-357, 199X-In this study we addressed the effects of the S-HT, receptor antagonist sertindole in rats. 
The compound was administered in doses of 0.08. 0.32, and 1.28 mg/kg, whereas a control group received the solvent. The 
effects of sertindole on sleep-wake states, behavioral patterns, and background electroencephalogram were studied. Following 
injection of drug or solvent, we recorded the electroencephalogram nd electromyogram for two periods of 4 h in the dark 
period of the light-dark cycle on 2 successive days. On the 1st day sertindole induced asignificant increase indeep slow-wave 
sleep, but only with a dose of 0.32 mg/kg. Furthermore, a decrease in REM sleep in alI three drug groups was established. 
The suppression of REM sleep was still present on the 2nd day. Sertindole also induced a decrease in alternation between 
behavioral patterns on the 1st day. There were no significant changes inthe spectral content of the background eleetroencepha- 
logram. In a parallel experiment it appeared that sertindole had no main effects on epileptic spike-wave discharges. This was 
established with a dose of 1.28 mg/kg sertindole in rats with absence seizures. These Endings suggest that sertindole. similar 
to other compounds modulating 5-HT, receptors, influences leep-wake states in rats by decreasing REM sleep and mildly 
increasing deep slow-wave sleep, whereas behavioral variation is slightly diminished, with no effects on the background EEG 
and almost no effects on spike-wave discharges. 
Sertindole 5-HT2 antagonist Sleep-wake states Behavior EEG spectral analysis Spike-wave discharges 
AN EXTRA stimulant for investigating the biologic role of 
serotonin (5-H-l) in the regulation of vigilance and sleep-wake 
states stems from the discovery of selective ligands for central 
5-HT binding sites. Several subtypes of 5-HT receptors have 
already been identified (15). It has been shown in rats that 
compounds which particularly modulate the 5-HT2 receptor 
influence sleep-wake states. For example, 5.HT, antagonists 
such as mianserin and ritanserin increase deep slow-wave 
sleep, which is accompanied by a decrease of REM sleep (1 l- 
13). A decrease of REM sleep was not found for RP 62203, a 
newer 5.HT, antagonist, which also enhanced deep slow-wave 
sleep (28). In accordance with this it was noted that the admin- 
istration of selective 5-HT uptake inhibitors gives rise to in- 
creased waking (32). 
A new drug with promising biologic effects is sertindole, a 
powerful 5-HTz receptor antagonist (25). The question put 
forward in this experiment was whether sertindole also has 
effects on sleep-wake states and furthermore, on behavioral 
parameters, because it is preferable that putative hypnotics 
should only promote sleep without affecting behavioral pat- 
terns. Also, the effects of sertindole on the spectral content of 
the background electroencephalogram (EEG) were estab- 
lished. Classification of drugs according to their pharmaco- 
logic EEG fingerprint is increasingly important (8,20,36). 
Because it is known that drugs influencing sleep-wake 
states may also affect epileptic discharges, the putative epi- 
lepsy-modulating properties of sertindole were evaluated in a 
parallel experiment. This was carried out in rats of the epilep- 
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tic WAG/Rij strain, which is considered to be a model for 
human absence pilepsy. In this model various drugs influenc- 
ing several neurotransmitters have already been tested (6,7) 
but serotonergic drugs still have not been evaluated. 
METHOD 
We used 36 adult male Wistar rats, with an age of about 6 
mo and a body weight between 270 and 450 g, in the first 
experiment. They were housed singly and had free access to 
standard food and water. Animals were maintained on a 12 
L : 12 D cycle with 500-600 lx white lights on at 2000 h, and 
2-3 lx red lights on in the dark period. The latter allowed 
observation of the animals in the dark period. Under deep 
sodium pentobarbital anesthesia, each rat was provided with 
a cortical tripolar EEG electrode set (MS 333/2-A; Plastics 
One, Roanoke, VA). With skull surface flat and bregma zero- 
zero, electrodes were placed over the anterior and posterior 
regions, with coordinates A 2.0, L 3.5, and A - 6.0, L 4.0, 
respectively, whereas the ground electrode was placed over the 
cerebellum. Electromyogram (EMG) electrodes (MS 303/71; 
Plastics One) were placed subcutaneously (SC) over the dorsal 
neck muscles. Each animal was allowed to recover completely 
after surgery and was then housed in a transparent recording 
cage and adapted to the recording leads for 48 h. 
Animals were allocated to four groups, each containing 
nine subjects. At the 1st experimental day, animals were in- 
jected intraperitoneally (IP) at 0000 h with solvent (solvent 
group) or sertindole in doses of 0.08, 0.32, and 1.28 mg/ 
kg (groups 0.08, 0.32, and 1.28, respectively). Sertindole was 
dissolved in 0.1 M HCI diluted with water, and the pH ad- 
justed until it was between 6 and 7, with some drops of 0.1 M 
NaOH. After injection, EEG and EMG recordings were made 
for 4 h. This was done in the dark period, which is suitable to 
establish hypnotic effects (36). Considering the long duration 
of action of sertindole (25), a second recording period of 4 h 
was performed on the 2nd experimental day, starting 22 h 
after injection. 
Signals were amplified and filtered by an Elema- 
Schonander polygraph (Solna, Sweden), which allowed EEG 
frequencies between 1 and 70 Hz and EMG frequencies be- 
tween 27 and 700 Hz to pass. Signals were stored on magnetic 
tape (SE 7000, Cambridge, UK). Subsequently, the two 4-h 
periods were analyzed off-line with an automatic sleep-wake 
classification system. Based on EEG and EMG signals, this 
system is able to discriminate between wakefulness, REM 
sleep, light slow-wave sleep, and deep slow-wave sleep (33). 
The spontaneous behavior of the rats was observed for 30 
min, starting 1 h after drug or solvent injection. Behavioral 
observation was again performed in the second recording pe- 
riod for 0.5 h, beginning 1 h after the start of this period. 
Behavioral categories that were scored were exploratory be- 
havior such as walking, rearing, sniffing, and digging; auto- 
matic behavior such as grooming, eating, and drinking; and 
immobile behavior such as sitting, lying, and standing still 
(5,7). Behavioral observations were analyzed with a computer 
software system (23). 
The spectral content of the EEG was established during 
waking immobility. The EEG associated with this state is sen- 
sitive to drug-induced changes (36). Successive EEG periods 
of minimally 40 s were digitized at a rate of 512 samples/s. 
The power spectrum was calculated with a fast Fourier trans- 
formation and normalized (mean = 0, variance = 1) to com- 
pensate for different amplification values. This provides the 
Z-scores of the EEG power. We distinguished the &band (l-4 
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Hz), O-band (6-10 Hz), u-band (11-14 Hz), p-1 band (15-30 
Hz), and 8-2 band (> 30 Hz) (7). 
Statistical significance of the drug effects was determined 
by means of analysis of variance (ANOVA) with dose as fac- 
tor. When significant dose effects were found, differences be- 
tween groups were subsequently tested with Duncan’s multi- 
ple-range test, with a! = 0.05. 
Sixteen male WAG/Rij rats about 8 mo of age and weigh- 
ing between 330 and 380 g were used in the second experiment, 
in which the potential effects of sertindole on spike-wave dis- 
charges were established. Rats were maintained under identi- 
cal conditions as those in the previous experiment; the surgical 
and experimental treatments were also the same, except that 
no EMG electrodes were placed. EEG recordings took place 
in the dark phase of the day, which is the time with the highest 
incidence of spike-wave discharges (35). Two groups of rats 
were formed: a sertindole and a solvent group (n = 8). At 
1000 h, animals were given solvent IP or sertindole in a dose 
of 1.28 mg/kg, a dose based on pilot work. Subsequently, the 
EEG was recorded for 2 consecutive h. The EEG was stored 
in digitized form on a magneto-optical disk (AT-CODAS; 
DataQ Instruments, Akron, OH). Spike-wave discharges were 
visually scored according to criteria elaborated elsewhere (34). 
Number, mean duration, and total duration of spike-wave 
discharges were determined over the 2-h lasting recording pe- 
riod. Differences between the two groups were evaluated with 
Student’s t-test for independent groups. 
RESULTS 
Sleep- Wake States 
The percentages of the several sleep-wake states deter- 
mined in the solvent group during the first recording period of 
4 h (day 1) were for wakefulness (W) 65.2 f 3% (mean + 
SEM), for light slow-wave sleep (L-SWS) 17.4 k 2.0%, for 
deep slow-wave sleep (D-SWS) 11.6 f 1.69’0, and for REM 
6.1 + 1.1%. Figure 1 presents the occurrence of these states 
determined in the solvent and the drug groups during the first 
and second recording periods of 4 h (days 1 and 2). The differ- 
ences between groups on day 1 were evaluated, and the 
ANOVA showed a significant effect for the percentage of 
D-SWS [F(3, 32) = 4.56, p < 0.011 and the percentage of 
SLEEP-WAKE STATES 
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FIG. 1. Effects of three doses of sertindole (0.08, 0.32, and 1.28 
mg/kg) and solvent (0.00 mg/kg) on the percentage of time of W 
(wakefulness), L-SWS (light slow-wave sleep), D-SWS (deep slow- 
wave sleep), and REM (REM sleep) on days 1 and 2. Means and SEMs 
are indicated (*p < 0.01 compared with the control group). 
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FIG. 2. Effects of three doses of sertindole (0.08,0.32, and 1.28 mg/ 
kg) and solvent (0.00 mg/kg) on the number of behavioral periods of 
EXP (exploratory behavior), AUT (automatic behavior), and IMM 
(immobile behavior) on days 1 and 2. Means and SEMs are indicated 
(*p c 0.01 compared with the control group). 
REM t-3, 32) = 4.51, p < 0.011. The posthoc tests revealed 
a higher percentage of D-SWS in group 0.32 compared to all 
other groups, whereas all drug groups had a lower percentage 
of REM than the solvent group. 
In the second recording period of 4 h, beginning 22 h after 
solvent injection (day 2), the percentages were for W: 71.3 f 
2.2%; for L-SWS: 15,6 f 1.8%; for D-SWS: 5.4 f 1.2%; 
and for REM: 7.4 f 1.6%. The percentages of W [F(3, 32) 
= 3.64, p c 0.051 and REM [fl3, 32) = 4.07, p < 0.051 
were significantly affected by sertindole. Group 1.28 had a 
lower percentage W than all other groups, and the solvent 
group had a higher percentage REM than the groups 0.08 and 
0.32. 
Behavioral Categories 
Sertindole did not induce differences in the total duration 
of each of the three behavioral categories, but differences were 
found in the number of times that exploratory behavior [F(3, 
31) = 3.17, p < 0.051 and automatic behavior [F(3, 31) = 
3.61, p < 0.051 occurred (Fig. 2). On day 1, groups 0.32 and 
1.28 had fewer periods of exploratory behavior than the sol- 
vent group and group 0.08, and the same was true for auto- 
matic behavior. On day 2 there were no further differences. 
When the number of shifts between the three behavioral cate- 
gories were taken together, a significant difference between 
the three groups emerged only on day 1 [F(3, 31) = 4.01, p 
< 0.011. The solvent group and group 0.08 had more alter- 
ations than groups 0.32 and 1.28. 
Spectral EEG Analysis 
The ANOVA on the normalized Z-scores of the 6-, 0, u-, 
8-1, and 8-2 EEG bands showed no significant changes be- 
tween groups either on day 1 or day 2. 
Epileptic Activity 
The t-test for independent groups over the total period of 2 
h revealed no differences between the solvent and sertindole 
groups on the number of spike-wave discharges (mean number 
f SEM: sertindole 31 f 8; solvent 27 f 8) and on the total 
duration of these discharges (sertindole 404 f 131 s; solvent 
248 f 103 s). A marginal significant increase was found in 
the mean duration of spike-wave discharges (sertindole 11.4 
f 1.5 s; solvent 7.6 f 1.1 s; t = 2.03, df 14, p < 0.07). 
Data are shown in Fig. 3. 
DISCUSSION 
The present results demonstrate that the 5-HT2 receptor 
antagonist sertindole exerted an effect on slow-wave sleep as 
well on REM sleep. Deep slow-wave sleep increased, but only 
at a dose of 0.32 mg/kg. The fact that the increase in deep 
slow-wave sleep was only seen at a moderate dose and disap- 
peared on day 2 suggests that this effect was relatively mild. 
On the other hand, REM sleep decreased with all doses of 
sertindole on day 1, whereas two doses of sertindole (0.08 and 
0.32) continued to decrease REM sleep on day 2. The smaller 
effects on day 2, 22-26 h after injection, are in line with the 
half-life of sertindole, which is on the order of 13 h in the rat 
(25). An exception to the generally smaller effects on day 2, 
and probably a chance finding, was that the highest dose of 
sertindole decreased waking time only on that day. 
Comparable effects of 5-HT, antagonists on sleep-wake 
states in rats are described in the literature, although in most 
studies an increase of slow-wave sleep was only found in the 
light period of the light-dark cycle (11). Silhol et al. (27) found 
that ritanserin decreased waking, increased the deeper but not 
the deepest slow-wave sleep, and decreased REM sleep, pre- 
sumably by hindering entrance into this type of sleep. In 
agreement with this, Dugovic et al. (13) and Dugovic and 
Wauquier (12) noticed an increase in deep slow-wave sleep 
together with a decrease in REM sleep, whereas Borbely et al. 
(4) only found a decrease of REM sleep. Also, RP 62203, 
another 5-HT, antagonist, enhances deep slow-wave sleep in 
rats (28). Tortella et al. (30) concluded that 5-HT2 antagonists 
suppress REM sleep only in rats. From these data it can be 
stated that these drugs, which are all regarded as relatively 
specific 5-HT2 antagonists, decrease REM sleep and have a 
tendency to increase deep slow-wave sleep. The present results 
obtained with sertindole consistently fit into this general pic- 
ture. The question nevertheless remains whether these 5-HT, 
receptor antagonists can also influence similar receptors such 
as 5-I-IT,, and other receptor sites, which can also modulate 
sleep-wake states (9,29). The view that 5-HT, receptor antago- 
nists should be regarded as modulators of slow-wave sleep (11) 
is underscored by the present results. 
SPIKE-WAVE DISCHARGES 
d 
FIG. 3. Effect of 1.28 mg/kg sertindole and solvent on number, 
mean duration, and total duration of spike-wave discharges in epilep- 
tic rats. Means and SEMs are presented. No significant differences 
existed between groups. 
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In humans ritanserin as well as seganserin have also been 
shown to increase slow-wave sleep (10,17,18,26). Idzikowski 
et al. (18) showed that ritanserin enhanced the proportion 
of deep slow-wave sleep, whereas Ujszaszi (31) proved that 
sleepiness in healthy subjects was significantly increased in 
parts of the day with a high sleep propensity. Mianserin, an- 
other central serotonin antagonist that is used as an antide- 
pressant, has consistent but small suppressive ffects on REM 
sleep (21). It is suggested that mianserin has sedative and hyp- 
notic effects, because intermittent waking during sleep is re- 
duced (21). Adam and Oswald (1) noted that ritanserin pro- 
duces some improvement of sleep in middle-aged insomniacs. 
Nevertheless, none of these drugs has replaced the classical 
benzodiazepines as hypnotic. Serotonin antagonists are only 
prescribed when disturbances of sleep-wake rhythmicity have 
a behavioral or psychiatric background. They are given to 
improve sleep continuity and subjective well-being during the 
day. In line with this, Monti et al. (22) reported improved 
sleep and mood in abstinent alcoholic patients. In a recent 
consensus report, Borbely et al. (3) also concluded that the 
therapeutic profile of serotonergic drugs differ from that of 
the classical benzodiazepine hypnotics. 
Sertindole had no effect on the EEG spectrum, although 
the increase of deep slow-wave sleep would suggest more 6- 
activity. This increase is obviously restricted to sleep and does 
not take place during quiet wakefulness, during which condi- 
tion the effects on the EEG can most easily be established 
(36). There are also no main changes on epileptic activity in 
the EEG. There is a significant effect neither on the number 
of spike-wave discharges nor on the total duration of epileptic 
activity, despite a tendency to increase the total epileptic activ- 
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ity can be inferred from Fig. 3. The reason is that it marginally 
significantly increases the mean duration of spike-wave dis- 
charges. This means that serotonergic antagonists of the ser- 
tindole type are not, or only minimally, involved in the modu- 
lation of spike-wave discharges. 
Despite numerous studies, the role of the serotonergic sys- 
tem in the mediation of anxiety remains unclear (2,16,19). The 
best evidence for an anxiolytic effect are those drugs having 
agonistic properties at S-HT,, receptors, such as buspirone 
and ipsapirone (14). Sanchez et al. (24,25) suggested that ser- 
tindole is a putative neuroleptic with a high limbic selectivity, 
which exerts potent anxiolytic effects in rodents. The anxio- 
lytic profile is different from that of the benzodiazepines and 
the S-HT,, receptor agonists. In a series of tests, Sanchez et 
al. (24,25) showed, among others, that sertindole decreases 
locomotor activity in rats. In the present experiment, sertin- 
dole gave rise to a decrease in the number of shifts between 
exploratory and automatic behavior and, furthermore, to a 
decrease in the general number of shifts between behavioral 
categories. It cannot be excluded that sertindole yields a more 
relaxed behavioral state, although a more sedative state also 
cannot be excluded. 
In conclusion, sertindole exerts effects on sleep-wake states 
with a mild increase in deep slow-wave sleep and a decrease in 
REM sleep, in the same line as other 5-HT, receptor antago- 
nists. Further, it has only slight effects on behavior and no 
effects on the frequency spectrum of the background EEG, 
as we11 as no main effects on the occurrence of spike-wave 
discharges. Therefore, sertindole seems to be a new and prom- 
ising drug that merits clinical attention in the field of sleep 
research. 
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